Zobrazeno 1 - 10
of 67
pro vyhledávání: '"R. Beume"'
Autor:
Antonio Piccoli, Licia Totani, C. Amore, Nicola Martelli, A. Di Santo, V. Evangelista, H. Tenor, R. Beume, Giuseppe Dell'Elba
Publikováno v:
Journal of Thrombosis and Haemostasis. 14:191-204
UNLABELLED ESSENTIALS: Thrombosis is a major comorbidity in patients with chronic obstructive pulmonary disease (COPD). Roflumilast is a selective phosphodiesterase type-4 (PDE4) inhibitor approved for treatment of severe COPD. PDE4 blockade by roflu
Autor:
B. Hauns, H. Heinzerling, G. Grentzmann, R. Beume, S. Sanjar, K. Melchers, M. Elmlinger, K. Schoenfeld, S. L. Wollin, R. Hermann, C. Hesslinger
Publikováno v:
Pneumologie. 60
Publikováno v:
Drugs under experimental and clinical research. 31(1)
Rheumatoid arthritis (RA) is a disease that is still insufficiently controlled by current treatments. Methotrexate (M7X), a small molecular weight compound, has been the gold standard in the treatment of RA. It has several anti-inflammatory activitie
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 297(1)
We have investigated the bronchodilator and anti-inflammatory properties of roflumilast (3-cyclopropylmethoxy-4-difluoromethoxy-N-[3,5-dichloropyrid-4-yl]-benzamide), a novel, highly potent, and selective phosphodiesterase 4 (PDE4) inhibitor. Additio
Publikováno v:
Experimental lung research. 20(3)
Zardaverine (Byk Gulden, Konstanz, Germany) is a new selective phosphodiesterase (PDE) III/IV inhibitor. The bronchodilating and bronchoprotective potency of zardaverine and the nonselective PDE inhibitor theophylline was compared by measuring typica
Publikováno v:
Pulmonary pharmacology. 6(4)
Summary: In a placebo-controlled study, the characteristics and duration of action of a commercially available bovine lung surfactant factor (LSF; 50 mg/kg body weight) were investigated in premature lambs at 124-127 days gestational age. Exact matin
Publikováno v:
Pulmonary pharmacology. 6(1)
Summary: During pressure- or volume-controlled ventilation different surfactant preparations were compared in an improved rabbit fetus model. Based on a self-designed software program, this model enables on-line registration of lung mechanics and hea
Publikováno v:
Agents and actions. Supplements. 34
Zardaverine is shown to inhibit selectively two out of five isoenzyme classes of phosphodiesterases, namely PDE III from human platelets and PDE IV from human polymorphonuclear leucocytes (PMN) with IC50 values of 0.58 and 0.17 microM, respectively.
Publikováno v:
Agents and actions. Supplements. 34
Publikováno v:
The Journal of Pharmacology and Experimental Therapeutics; April 2001, Vol. 297 Issue: 1 p280-90, 11p